Wednesday, December 17, 2025 Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study A CCTG poster presentation at the Society for Neuro-Oncology Annual Meeting, held November 19-23, 2025 in Honolulu. The abstract was then published in the journal Neuro-Oncology. Patients with progressive IDH-mutant grade 2-3 glioma have limited therapeutic options. The LUMOS1 pilot study established feasibility of a precision oncology approach using molecular profiling, with LUMOS2 introducing therapeutic arms. Thavaneswaran S, Koh E-S, Sim H-W, Ballinger ML, Thomas DM, Barnes EH, Kong B, O’Callaghan C, Pitz M, Hawkins C, Roberge D, Pallimulla S, Ralston L, Yip S, Day BW, Verhaak RGW, Buckland M, Amanuel B, Simes J, De Lourenco RA, Solano NZ, Calder R, Adda L, Ahern E, Cooper A, Dowling A, Harrup R, Kichenadasse G, Lau B, Lynam J, Lwin Z, Wheeler H, Whittle JR, Norrie A, Harrison R, Mason WP, de Robles P, Maddula M, K Gan H. TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study. Society for Neuro-Oncology Annual Meeting. Neruo-Oncology 27 [Supplement_5], v423-v424. 2025.https://doi.org/10.1093/neuonc/noaf201.1676
